leisure time -WSS

leisure time

author：knowledge 2025-09-05 09:13:21 - browse：443

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Virginia high school admissions case could be legal follow
Next article： What happened to the House vote on health price transparency?

WSS

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Diversity in medical illustrations gets boost from Chidiebere Ibe

Apellis safety probe of eye disease drug centers on injection needle

How a symptom of dementia informs our understanding of creativity

Senate bill would ban some hospital facility fees

What happened to the House vote on health price transparency?

hotspot

leisure time

hotspot

Bright Health sells Medicare Advantage business to Molina

People with substance use disorder deserve online privacy

Medicare details structure of new drug price negotiation program

Medicare explains how it will choose drugs for negotiation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AstraZeneca challenges Medicare drug negotiation program

Drug repurposing or repositioning? The language matters

People with substance use disorder deserve online privacy

At least 13 dead in Texas as scorching temps continue

Akili changes sales model for its ADHD video game treatment

Wikipedia

Transgender sports debate: Physicians say bans are health issue

In science, is the line between industry and academia shifting?

Why the quest to eradicate polio has stumbled

Chamber of Commerce, DOJ clash in court over drug prices

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Neurocrine congenital adrenal hyperplasia trial succeeds

hotspot

explore

hotspot

focus